THRX NASDAQ
Cambridge, MA 02142
US
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yi Kathy | D-Return | 3,250 | — | 2024-02-14 |
| Yi Kathy | D-Return | 99,634 | $4.03 | 2024-02-14 |
| Stein Steven H | D-Return | 3,250 | — | 2024-02-14 |
| ORBIMED ADVISORS LLC | U-Tender | 650,600 | $4.05 | 2024-02-14 |
| HAYDEN DONALD J JR | U-Tender | 10,000 | $4.05 | 2024-02-14 |